Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9199 USD | -0.49% | -9.81% | -34.29% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
Evolution of the average Target Price on Seres Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Seres Therapeutics, Inc.
Oppenheimer | |
Chardan Research | |
Goldman Sachs | |
JPMorgan Chase | |
Canaccord Genuity | |
Piper Sandler | |
HC Wainwright | |
Chardan |
EPS Revisions
- Stock Market
- Equities
- MCRB Stock
- Consensus Seres Therapeutics, Inc.